NCT06869174View on ClinicalTrials.gov

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 8, 2025

Primary Completion Date

March 8, 2027

Study Completion Date

August 8, 2028

Conditions
Cancer of Unknown Primary
Interventions
DRUG

Pucotenlimab combined with MRG002

Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Zhiguo Luo, MD, PhD

OTHER